Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All our eyes on the (not so) distant Horizant as XenoPort seeks shelter from storm

This article was originally published in Scrip

Executive Summary

As XenoPort halted development of arbaclofen as a treatment for gastro-oesophageal reflux disease (GORD), the attention of investors and analysts is turning back to the stalled regulatory status of the company’s candidate product in restless legs syndrome, Horizant (gabapentin enacarbil). As the product approaches its new PDUFA date of 6 April, some analysts consider that concerns at the FDA that the compound may cause pancreatic cancer are unfounded. Nevertheless, FDA unpredictability and an understandable lack of urgency in a well-populated RLS market still casts a cloud over the product.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts